<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770753</url>
  </required_header>
  <id_info>
    <org_study_id>AG348-C-017</org_study_id>
    <secondary_id>2021-000211-23</secondary_id>
    <nct_id>NCT04770753</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)</brief_title>
  <acronym>ENERGIZE</acronym>
  <official_title>A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agios Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agios Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the effect of mitapivat versus placebo on&#xD;
      anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mitapivat group will include approximately 114 participants. The placebo group will&#xD;
      include approximately 57 participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Hemoglobin (Hb) Response</measure>
    <time_frame>Baseline, Week 12 up to Week 24</time_frame>
    <description>Hb response is defined as a ≥1.0 gram per deciliter (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score from Week 12 through Week 24</measure>
    <time_frame>Baseline, Week 12 up to Week 24</time_frame>
    <description>The 13-item FACIT-Fatigue subscale assesses severity and impact of fatigue. The subscale has a 7-day recall period, and total score ranges from 0 to 52, with a higher score indicating less fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Hb Concentration From Week 12 through Week 24</measure>
    <time_frame>Baseline, Week 12 up to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hb 1.5+ Response</measure>
    <time_frame>Baseline, Week 12 up to Week 24</time_frame>
    <description>Hb 1.5+ response is defined as a ≥1.5 g/dL increase in average Hb concentration from Week 12 through Week 24 compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Indirect Bilirubin at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Haptoglobin at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reticulocytes at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erythropoietin at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in the Patient Global Impression of Severity (PGIS) -Fatigue by at Least 1 Category at Weeks 12, 16, 20, and 24 Compared With Baseline, or &quot;No Change&quot; if No or Mild Fatigue at Baseline</measure>
    <time_frame>Baseline, Weeks 12, 16, 20, and 24</time_frame>
    <description>The PGIS-Fatigue assesses severity of fatigue (on a 4-point scale ranging from &quot;None&quot; to &quot;Severe&quot;) over a 7-day recall period. Improvement in the PGIS-Fatigue by at least one category or no change if &quot;None&quot; or &quot;Mild&quot; PGIS-Fatigue response at baseline will be assessed separately at Weeks 12, 16, 20, and 24 compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in the Patient Global Impression of Change (PGIC) -Fatigue at Weeks 12, 16, 20, and 24, or &quot;No Change&quot; if No or Mild Fatigue at Baseline</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The PGIC-Fatigue assesses change in fatigue compared with baseline (on a 5-point scale ranging from &quot;Much better&quot; to &quot;Much worse&quot;). Participants reporting improvement in the PGIC-Fatigue or reporting &quot;No change&quot; if &quot;None&quot; or &quot;Mild&quot; PGIS-Fatigue response at baseline will be assessed separately at Weeks 12, 16, 20, and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Ferritin at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Transferrin Saturation (TSAT) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 293</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Graded by Severity</measure>
    <time_frame>Up to Week 293</time_frame>
    <description>AEs and SAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03) from Grades 1 to 4 where Grade 1 is mild and Grade 4 is life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Up to Week 293</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Up to Week 293</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma or Blood Concentrations Over Time for Mitapivat</measure>
    <time_frame>Pre-dose Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Mitapivat</measure>
    <time_frame>Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Mitapivat</measure>
    <time_frame>Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Plasma Concentration (Tmax) of Mitapivat</measure>
    <time_frame>Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Concentration of Adenosine Triphosphate (ATP)</measure>
    <time_frame>Pre-dose Day 1; pre-dose Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Concentration of 2,3 - diphosphoglycerate (2,3-DPG)</measure>
    <time_frame>Pre-dose Day 1; pre-dose Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 20</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>Non-Transfusion-dependent Alpha-Thalassemia</condition>
  <condition>Non-Transfusion-dependent Beta-Thalassemia</condition>
  <arm_group>
    <arm_group_label>Mitapivat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double-blind Period: Participants will receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 24 weeks.&#xD;
Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-blind Period: Participants will receive placebo matching mitapivat, orally, BID for 24 weeks.&#xD;
Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Matching Mitapivat</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitapivat</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Mitapivat</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>AG-348</other_name>
    <other_name>AG-348 sulfate hydrate</other_name>
    <other_name>Mitapivat sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene&#xD;
             mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H [HbH]&#xD;
             disease) based on Hb electrophoresis, Hb high-performance liquid chromatography&#xD;
             (HPLC)), and/or deoxyribonucleic acid (DNA) analysis;&#xD;
&#xD;
          -  Hb concentration ≤10.0 grams per deciliter (g/dL) (100.0 grams per liter [g/L]), based&#xD;
             on an average of at least 2 Hb concentration measurements (separated by ≥7 days)&#xD;
             collected during the Screening Period;&#xD;
&#xD;
          -  Non-transfusion-dependent, defined as ≤5 red blood cell (RBC) units during the 24-week&#xD;
             period before randomization; and no RBC transfusions ≤8 weeks before providing&#xD;
             informed consent or during the Screening Period;&#xD;
&#xD;
          -  If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before&#xD;
             randomization;&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) and men with partners who are WOCBP must be&#xD;
             abstinent of sexual activities that may result in pregnancy as part of their usual&#xD;
             lifestyle or agree to use 2 forms of contraception, one of which must be considered&#xD;
             highly effective, from the time of providing informed consent, throughout the study,&#xD;
             and for 28 days after the last dose of study drug for women and 90 days after the last&#xD;
             dose of study drug for men. The second form of contraception can be an acceptable&#xD;
             barrier method;&#xD;
&#xD;
          -  Written informed consent before any study-related procedures are conducted and willing&#xD;
             to comply with all study procedures for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding;&#xD;
&#xD;
          -  Documented history of homozygous or heterozygous sickle hemoglobin (HbS) or hemoglobin&#xD;
             C (HbC);&#xD;
&#xD;
          -  Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;&#xD;
&#xD;
          -  Currently receiving treatment with luspatercept; the last dose must have been&#xD;
             administered ≥18 weeks before randomization;&#xD;
&#xD;
          -  Currently receiving treatment with hematopoietic stimulating agents; the last dose&#xD;
             must have been administered ≥18 weeks before randomization;&#xD;
&#xD;
          -  History of any malignancy, except for nonmelanomatous skin cancer in situ, cervical&#xD;
             carcinoma in situ, or breast carcinoma in situ. Participants must not have active&#xD;
             disease or received anticancer treatment ≤5 years before providing informed consent;&#xD;
&#xD;
          -  History of active and/or uncontrolled cardiac or pulmonary disease ≤6 months before&#xD;
             providing informed consent;&#xD;
&#xD;
          -  Hepatobiliary disorders;&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;45 milliliters per minute (mL/min)/1.73 m^2 by&#xD;
             Chronic Kidney Disease Epidemiology Collaboration creatinine equation;&#xD;
&#xD;
          -  Nonfasting triglycerides &gt;440 milligrams per deciliter (mg/dL) (5 millimoles per liter&#xD;
             [mmol/L]);&#xD;
&#xD;
          -  Active infection requiring systemic antimicrobial therapy at the time of providing&#xD;
             informed consent;&#xD;
&#xD;
          -  Positive test for hepatitis C virus antibody (HCVAb) with evidence of active HCV&#xD;
             infection, or positive test for hepatitis B surface antigen (HBsAg);&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus (HIV)-1 antibody (Ab) or HIV-2 Ab;&#xD;
&#xD;
          -  History of major surgery (including splenectomy) ≤16 weeks before providing informed&#xD;
             consent and/or a major surgical procedure planned during the study;&#xD;
&#xD;
          -  Current enrollment or past participation (≤12 weeks before administration of the first&#xD;
             dose of study drug or a timeframe equivalent to 5 half-lives of the investigational&#xD;
             study drug, whichever is longer) in any other clinical study involving an&#xD;
             investigational treatment or device;&#xD;
&#xD;
          -  Receiving strong CYP3A4/5 inhibitors that have not been stopped for ≥5 days or a&#xD;
             timeframe equivalent to 5 half-lives (whichever is longer); or strong CYP3A4 inducers&#xD;
             that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives&#xD;
             (whichever is longer), before randomization;&#xD;
&#xD;
          -  Receiving anabolic steroids that have not been stopped for at least 4 weeks before&#xD;
             randomization. Testosterone replacement therapy to treat hypogonadism is allowed. The&#xD;
             testosterone dose and preparation must be stable for ≥10 weeks before randomization;&#xD;
&#xD;
          -  Known allergy to mitapivat or its excipients (microcrystalline cellulose,&#xD;
             croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate);&#xD;
&#xD;
          -  Any medical, hematological, psychological, or behavioral condition(s) or prior or&#xD;
             current therapy that, in the opinion of the Investigator, may confer an unacceptable&#xD;
             risk to participating in the study and/or could confound the interpretation of the&#xD;
             study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Affairs</last_name>
    <role>Study Chair</role>
    <affiliation>Agios Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Affairs</last_name>
    <phone>833-228-8474</phone>
    <email>medinfo@agios.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>alpha-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

